Science-Business eXchange

, Volume 3, Issue 32, pp 972–972 | Cite as

Peripheral CNR1 antagonists to the fore

  • Michael J. Haas


An NIH-Northeastern team has demonstrated that peripheral inhibition of the cannabinoid CB1 receptor could treat obesity and related metabolic disorders without the safety issues posed by CNS-acting compounds like Acomplia rimonabant. The results should boost efforts by Jenrin Discovery and 7TM Pharma to develop inhibitors for these indications.

Copyright information

© Nature Publishing Group 2010

Authors and Affiliations

  • Michael J. Haas

There are no affiliations available

Personalised recommendations